Search Results
You are looking at 1 - 3 of 3 items for
- Author: EA Smith x
- Refine by access: All content x
Search for other papers by MW Smith in
Google Scholar
PubMed
Search for other papers by EA Espiner in
Google Scholar
PubMed
Search for other papers by TG Yandle in
Google Scholar
PubMed
Search for other papers by CJ Charles in
Google Scholar
PubMed
Search for other papers by AM Richards in
Google Scholar
PubMed
Metabolism of natriuretic peptides is regulated by two degradative pathways: uptake by the clearance receptor (natriuretic peptide receptor C--NPR-C) and hydrolysis by neutral endopeptidase (NEP). Affinity studies favour a dominant role of NPR-C in hormone degradation in several species but do not account for the efficacy of NEP inhibitors in vivo, nor the uniquely prolonged half life (t((1/2))) of human brain natriuretic peptide (hBNP). Postulating that (1) delayed metabolism of hBNP reflects resistance to NEP and (2) interactions between NPR-C and NEP increase enzyme activity, we have used purified ovine and human NEP, plus ovine lung plasma membranes to study the relative importance of receptor and enzyme pathways. We have also related the findings to hormone metabolism in vivo. Binding affinities of atrial natriuretic peptide (ANP), hBNP and ovine BNP (oBNP) to oNPR-C were similar (K(d)=8-16 pM). In contrast, unlike ANP and oBNP, hBNP was not significantly degraded by purified oNEP or plasma membranes. Despite similar (and high) affinity of oNPR-C for oBNP and hBNP, the t((1/2)) of hBNP (12.7 min) was more than fourfold that of oBNP (2.6 min). Although we found no evidence for receptor-enzyme interaction, our results show that the delayed metabolism of hBNP reflects resistance to NEP. These findings have important implications for future treatment strategies in human disease.
Search for other papers by A.I. Smith in
Google Scholar
PubMed
Search for other papers by C.A. Wallace in
Google Scholar
PubMed
Search for other papers by R.L. Moritz in
Google Scholar
PubMed
Search for other papers by R.J. Simpson in
Google Scholar
PubMed
Search for other papers by L.B. Schmauk-White in
Google Scholar
PubMed
Search for other papers by E.A. Woodcock in
Google Scholar
PubMed
Search for other papers by J.W. Funder in
Google Scholar
PubMed
ABSTRACT
Though minor sequence differences between-species have been reported for adrenocorticotrophin, ACTH(1–39), the steroidogenic moiety ACTH(1–24) has appeared invariant in mammals. We here report the isolation, purification and amino acid sequencing of guinea-pig (GP) ACTH in which Pro24 is replaced by [ill] Ala24, and the demonstration that GP-ACTH stimulates aldosterone production to maximal levels well above those seen with human ACTH(1–39) or Synacthen, ACTH(1–24) amide, the synthetic ACTH fragment widely used for diagnostic and therapeutic purposes.
Search for other papers by EA Smith in
Google Scholar
PubMed
Search for other papers by EP Frankenburg in
Google Scholar
PubMed
Search for other papers by SA Goldstein in
Google Scholar
PubMed
Search for other papers by K Koshizuka in
Google Scholar
PubMed
Search for other papers by E Elstner in
Google Scholar
PubMed
Search for other papers by J Said in
Google Scholar
PubMed
Search for other papers by T Kubota in
Google Scholar
PubMed
Search for other papers by M Uskokovic in
Google Scholar
PubMed
Search for other papers by HP Koeffler in
Google Scholar
PubMed
This study explores the effects of chronic administration of vitamin D(3) compounds on several biological functions in mice. Knowledge of long-term tolerability of vitamin D(3) analogs may be of interest in view of their potential clinical utility in the management of various pathologies such as malignancies, immunological disorders and bone diseases. Four unique vitamin D(3) analogs (code names, compounds V, EO, LH and LA) and 1,25-dihydroxyvitamin D(3) (1, 25(OH)(2)D(3)) were administered i.p. for 55 weeks to Balb/c mice. Each analog had previously been shown to have potent in vitro activities. After 55 weeks of administration, the mice had a profound decrease in their serum levels of interleukin-2 (IL-2). Likewise, several analogs depressed serum immunoglobulin G concentrations (compounds LH and LA), but levels of blood lymphocytes and splenic lymphocyte subsets (CD4, CD8 and CD19) were not remarkably depressed. The percent of committed myeloid hematopoietic stem cells was 4- to 5-fold elevated in the bone marrow of the mice that received analogs LH and V; nevertheless, their peripheral blood white and red cell counts and platelets were not significantly different in any of the groups. The mice that received 1,25(OH)(2)D(3) had a decrease in bone quantity and quality with a decrease in cross-sectional area and cortical thickness, and a 50% reduction in both stiffness and failure load compared with the control group. In contrast, the cohort that received a fluorinated analog (compound EO) developed bones with significantly larger cross-sectional area and cortical thickness as well as stronger mechanical properties compared with the control group. At the conclusion of the study, body weights were significantly decreased in all experimental mice. Their blood chemistries were normal. Extensive gross and microscopic autopsy analyses of the mice at the conclusion of the study were normal, including those of their kidneys. In conclusion, the vitamin D(3) analogs were fairly well tolerated. They did suppress immunity as measured by serum IL-2 and may provide a means to depress the immune response after organ transplantation and for autoimmune diseases. Use of these analogs prevented the detrimental effects of vitamin D(3) administration on mechanical and geometric properties of bone, while one analog (compound EO) actually enhanced bone properties. These results suggest that long-term clinical trials with the analogs are feasible.
